Filing Flows › Comparisons › BDPT vs IBO
Bioadaptives vs Impact Biomedical: BDPT and IBO compared
Bioadaptives is the larger company: $5K of revenue in its latest quarter (Q2 2026) against $3K for Impact Biomedical (Q2 2026). Bioadaptives is growing faster (+55% against -57% a year earlier).
Where the money goes: BDPT and IBO
Bioadaptives (BDPT) · Q2 2026
Bioadaptives, Q2 2026: revenue $5K (+55% year over year), net earnings $150K, operating cash flow −$44K. The chart follows the revenue to costs, profit and cash.
Impact Biomedical (IBO) · Q2 2026
Impact Biomedical, Q2 2026: revenue $3K (-57% year over year), net loss $700K, operating cash flow $470K. The chart follows the revenue to costs, profit and cash.
| Bioadaptives (BDPT) | Impact Biomedical (IBO) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q2 2026 |
| Revenue | $5K | $3K |
| Revenue growth, Y/Y | +55% | -57% |
| Operating margin | n/m | n/m |
| Net earnings | $150K | −$700K |
| Operating cash flow | −$44K | $470K |
Questions
Which is bigger, Bioadaptives or Impact Biomedical?
Bioadaptives is the larger company: $5K of revenue in its latest quarter (Q2 2026) against $3K for Impact Biomedical (Q2 2026).
Is Bioadaptives or Impact Biomedical growing faster?
Bioadaptives is growing faster (+55% against -57% a year earlier).
More: Bioadaptives earnings · how Bioadaptives makes money · Impact Biomedical earnings · how Impact Biomedical makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 19, 2026; 10-Q filed Aug 7, 2026). Fiscal quarters can end on different dates. Not investment advice.